Search

News RETRO-TAS Study –⁠ Trifluridine/Tipiracil in Pretreated mCRC in Real-World Practice

How does trifluridine/tipiracil (FTD/TPI), which demonstrated efficacy in clinical trials in chemotherapy-refractory metastatic colorectal cancer (mCRC), fare in real-world practice? This was investigated by the authors of the Greek retrospective observational study RETRO-TAS.

Source: Treatment of Gastrointestinal Carcinomas 25. 5. 2023

News Study TACTIC –⁠ Efficacy and Safety of Trifluridine/Tipiracil in Pre-treated mCRC Patients in Real-world Practice

In the pivotal phase III RECOURSE randomized placebo-controlled study, therapy with trifluridine/tipiracil (FTD/TPI) was associated with improved overall survival and progression-free survival in pre-treated metastatic colorectal cancer (mCRC) patients. The below-presented TACTIC study provides prospective data from German real-world practice.

Source: Treatment of Gastrointestinal Carcinomas 25. 5. 2023

News Can Ketogenic Diet or Intermittent Fasting Help Patients with DM2 in Controlling Weight and Glycemia?

The foundation of managing type 2 diabetes mellitus (DM2) typically involves lifestyle adjustments, including dietary changes. Can intermittent fasting (IF) or the ketogenic diet (KD), popular dietary trends, help diabetics with weight loss and reduction of glycated hemoglobin (HbA1c) levels? The answer was sought by authors of a systematic review and meta-analysis comparing IF or KD with other dietary regimes.

Source: Modern Treatment of Diabetes 30. 5. 2023

News Vaccination and ALEmtuzumab: ALE when?

When, why and against what should patients with multiple sclerosis treated with alemtuzumab be vaccinated? And is vaccination effective in this population?

Source: Multiple Sclerosis 5. 6. 2023

News Traveling with MS –⁠ Is Vaccination a Limitation?

What about the need for vaccination when traveling abroad? Which vaccines should you be cautious about? And how to time vaccination concerning disease activity and the individual medications used in multiple sclerosis (MS) therapy?

Source: Multiple Sclerosis 5. 6. 2023

News Oral Azacitidine Prolongs Survival of AML Patients Regardless of Measurable Residual Disease

Intensive chemotherapy for patients newly diagnosed with acute myeloid leukemia (AML) often achieves high remission rates, although these remissions are often only temporary. Consolidation therapy with azacitidine (AZA) extends post-remission survival and disease-free intervals.

Source: Acute Myeloid Leukemia 6. 6. 2023

News Prediction of Hypocalcemia Risk in Patients Treated with Denosumab and Active Form of Vitamin D

According to new work by Japanese authors, it appears that the risk factors for the development of hypocalcemia in patients treated with denosumab and calcitriol (the active form of vitamin D) are different from those when natural vitamin D is added to denosumab.

Source: Prevention of Bone Events 8. 6. 2023

News Meta-analysis of Efficacy and Safety of Third-Generation Antiseizure Medications in Adjunctive Treatment of Focal Seizures in Adults with Epilepsy

Epilepsy treatment is primarily symptomatic, aimed at reducing seizure frequency. However, more than 50% of patients do not achieve seizure freedom with monotherapy. Below we summarize the results of a meta-analysis comparing the efficacy and safety of third-generation antiseizure medications in the treatment of focal seizures in adults with epilepsy.

Source: Epilepsy 8. 6. 2023

News Deficit dihydropyrimidine dehydrogenase and its association with 5-fluorouracil toxicity

Deficit dihydropyrimidine dehydrogenase (DPD) is a risk factor for severe toxicity of 5-fluorouracil (5-FU). Below, we summarize current knowledge regarding the identification of patients with pathogenic variants of the DPYD gene and study results concerning the safety of therapy with respect to dose individualization based on genotyping.

Source: Genetics 12. 6. 2023

News Compression therapy in combination with surgical intervention in the treatment of venous leg ulcers and prevention of their recurrence

Compression therapy represents an important part of the treatment of venous leg ulcers; it also plays a role in preventing possible recurrences. The 4-year British ESCHAR study evaluated the impact of combining compression therapy with surgical correction of reflux in the superficial venous system on the healing and potential recurrence of venous leg ulcers compared to compression therapy alone.

Source: Wound Healing 12. 6. 2023

News Comparison of the Risk of Interstitial Lung Disease in Patients with RA with Biological and Targeted Disease-Modifying Antirheumatic Therapy

The authors of a newly published study sought to answer whether the risk of developing interstitial lung disease in patients with rheumatoid arthritis (RA) is affected by the administration of biological or targeted disease-modifying antirheumatic therapy. They analyzed data from more than 28,000 patients with RA.

Source: Arthritis 8. 6. 2023

News Meta-analysis of the efficacy and safety of dupilumab in the treatment of atopic dermatitis in children and adults

Moderate to severe atopic dermatitis (AD) is accompanied by strong inflammatory processes that can occur anywhere on the skin, intense itching, and pain. The biologic dupilumab is a promising molecule for the treatment of severe forms of this condition –⁠ results from a recently published meta-analysis indicate that this therapy is not only effective but also well-tolerated by patients.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 13. 6. 2023

News Nonacog Beta Pegol (N9-GP) in Bleeding Prophylaxis in Patients with Hemophilia B –⁠ Real World Data

The goal of hemophilia B treatment is currently the prevention of bleeding by administering a coagulation factor IX concentrate. The study presented below brings recent real-world data on treatment outcomes when switching to the latest preparation, nonacog beta pegol (N9-GP).

Source: Hemophilia with Movement 13. 6. 2023

News Comparison of BEAM and TEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Lymphomas

At the beginning of this year, one of the few studies comparing the most commonly used conditioning regimen before autologous hematopoietic stem cell transplantation (ASCT) in patients with lymphomas (BEAM) with a regimen containing thiotepa instead of carmustine (TEAM) was published.

Source: Oncological Treatment 13. 6. 2023

News Clinical Profile and Outcomes of Patients with Cardiac Amyloidosis –⁠ Spanish Experience from Real Practice

Cardiac amyloidosis is caused by the deposition of amyloid fibrils in the myocardium and is among the diseases with significant diagnostic delay. Physicians from the University Hospital in Madrid shared their experiences with the diagnosis and treatment of these patients over the last decade in the cited work below.

Source: Amyloidosis 14. 6. 2023